SMMTSummit Therapeutics Inc.

Nasdaq summittxinc.com


$ 8.69 $ -2.23 (-20.47 %)    

Friday, 31-May-2024 15:30:06 EDT
QQQ $ 454.82 $ -0.01 (-0 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.59 (0.88 %)
TLT $ 91.26 $ 0.69 (0.77 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 8.685
$ 7.49
$ 0.00 x 0
$ 0.00 x 0
$ 7.49 - $ 10.10
$ 1.52 - $ 11.25
34,333,160
na
6.1B
$ -0.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-09-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citigroup-maintains-buy-on-summit-therapeutics-raises-price-target-to-13

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...

 summit-therapeutics-lung-cancer-therapy-ivonescimab-shows-improved-progression-free-survival-versus-mercks-multi-billion-keytruda-in-china-study

Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company ann...

Core News & Articles

Unprecedented: Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in Randomized Phase II...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION